BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Latest Pharma Insights


MeiraGTx acquires AAV gene therapy company Vector Neurosciences for up to $24mm
MeiraGTx Holdings PLC acquired privately held fellow gene therapy biotech Vector Neurosciences Inc. in an all-stock transaction, issuing a total of 225k Class A ordinary shares (valued at $3mm) to Vector’s stockholders.
Strategic Transactions - October 19, 2018
Celltrion, Emory team up in atherosclerosis
Celltrion Inc. is allying with Emory University in the discovery and development of therapies for atherosclerosis.
Strategic Transactions - October 19, 2018
KaNDy Therapeutics raises £25mm in Series C round
UK-based KaNDy Therapeutics (female sex-hormone related conditions) completed a £25mm ($32.2mm) Series C round from new backer Longitude Capital, along with returning investors Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners, and OrbiMed.
Strategic Transactions - October 19, 2018
Morphic closes $80mm Series B
Morphic Therapeutic Inc. (working on oral integrin therapies for autoimmune diseases, fibrotic diseases, and cancer) raised $80mm in its Series B financing led by Omega Funds and Novo Holdings, which each add a board member. New backers Invus and EcoR1 Capital were joined by Series A investors SR One, Pfizer Venture Investments, AbbVie Ventures, Polaris Partners, TA Springer (a board member), Schrodinger, and ShangPharma Investment Group. Morphic will use the proceeds to bring its two lead candidates through clinical proof-of-concept and to move other programs into human studies.
Strategic Transactions - October 19, 2018
AbbVie, Morphic ally in fibrosis
AbbVie Inc. and Morphic Therapeutic Inc. are teaming up to develop the latter’s oral integrin candidates for fibrosis-related indications, potentially including non-alcoholic steatohepatitis (NASH).
Strategic Transactions - October 19, 2018
Oxford Nanopore gets £50mm investment from Amgen
Closely held Oxford Nanopore Technologies Ltd. (genetic sequencing) received a £50mm ($66mm) equity investment from Amgen Inc. in a late-stage financing. Amgen’s deCODE genetics subsidiary has been using Nanopore’s technologies in its own genome research to discover and validate new targets.
Strategic Transactions - October 19, 2018
OliX Pharmaceuticals raises $38mm in IPO on KOSDAQ
South Korean RNAi therapeutics developer OliX Pharmaceuticals Inc. grossed KRW43bn ($38mm) in its initial public offering on the Korea Securities Dealer Automated Quotation (KOSDAQ) market through the sale of 1.2mm shares at $31.67.
Strategic Transactions - October 19, 2018
Aclaris nets $87mm through FOPO
Topical dermatology drug developer Aclaris Therapeutics Inc. netted $87.4mm in a public offering of 8.6mm shares at $10.75. Earlier this month, the company acquired Allergan's Rhofade (oxymetazoline) for $70mm and entered a concurrent loan facility with Oxford Finance. Aclaris will use the proceeds for a portion of the $65mm up-front payment to Allergan, to support commercialization activities for both Rhofade and Eskata (a hydrogen peroxide topical solution for seborrheic keratosis approved in December 2017 and launched earlier this year), and to fund R&D for other pipeline candidates.
Strategic Transactions - October 19, 2018
Novartis buys radiopharmaceuticals company Endocyte for $2.1bn
Novartis AG agreed to acquire public radiopharmaceuticals firm Endocyte Inc. (targeted cancer therapies and companion imaging agents) for $24 in cash per share (a 55% premium), for an equity value of $2.1bn (an enterprise value of $1.9bn, taking into account the company's cash on its balance sheet).
Strategic Transactions - October 19, 2018
Survey Shows Drug Makers Don't Expect To Begin Serializing All Packages By November Deadline
Concerns that the US pharmaceutical industry will not have the necessary serialization systems in place to fully comply with DSCSA...
The Pink Sheet - October 19, 2018
Pharma Q3 Results Preview: Biogen, Gilead, Celgene
Ozanimod re-filing is a big near-term catalyst for Celgene. Biogen investors will be looking for more information about the development...
The Pink Sheet - October 19, 2018
Deal Watch, Licensing & Alliances: Amgen Places $66m Bet On Genetic Sequencing
Already partnered with Oxford Nanopore through its acquisition of deCODE Genetics, Amgen invests in the UK biotech to enhance its...
The Pink Sheet - October 19, 2018
Deal Watch, M&A: Warp Drive And Its Partnerships Acquired By Revolution
Once expected to be absorbed by Sanofi, US biotech Warp Drive Bio now will become part of California’s Revolution Medicines...
The Pink Sheet - October 19, 2018
Only Health-Care Case At US Supreme Court This Fall Looks At Preemption
The Supreme Court will hear arguments this fall in a lawsuit concerning whether FDA decisions can protect drug manufacturers from...
Medtech Insight - October 19, 2018
Medtronic Vet Christopher Barry Takes Helm At Nuvasive
About three years after becoming CEO of NuVasive, Gregory Lucier is ceding the role to Barry, who has led Medtronic's...
Medtech Insight - October 19, 2018
With TheraFlu PowerPods, GSK Brews Market For OTCs From Coffee Makers
GSK takes Theraflu brand from medicine cabinet to kitchen with launch of PowerPods of OTC ingredients delivered through single-serve coffee...
The Pink Sheet - October 19, 2018
Hong Kong Medtech Regulators Face Need For System Update
Speed and efficiency are apparently on the minds of Hong Kong's regulators, who have proposed to shorten approval times for...
Medtech Insight - October 19, 2018
Q&A: Ireland's Success In Attracting Medtech Companies
Medtech Insight talked to Rachel Shelly, the Head of Medical Technologies for IDA Ireland, about the Irish government's continuing efforts...
Medtech Insight - October 19, 2018
Controversial Dengue Drug Among Six Products To Get EMA Thumbs Up
Dengvaxia, the dengue vaccine from Sanofi that was suspended in the Philippines last year, is among six new products to...
The Pink Sheet - October 19, 2018
PhaseBio nets $42.8mm via IPO
PhaseBio Pharmaceuticals Inc. netted $42.8mm in its initial public offering of 9.2mm common shares at $5 each on the Nasdaq. The company had planned to sell 5mm shares between $12 and $14 each.
Strategic Transactions - October 19, 2018
Every Little Helps: Shire Product Advances Fortify Takeda's Bid
A positive opinion in the EU for Shire's Takhzyro and a favorable US advisory committee vote for prucalopride are incremental...
The Pink Sheet - October 19, 2018
Voters Likely To Pick And Choose Among Device Industry Favorites In Close Races
Among the very tight Republican and Democrat contests anticipated in this November’s US midterm elections are more than a few...
Medtech Insight - October 19, 2018
DATA: Results Recap: Neovasc's Tiara TMVR Succeeds In 12 Patients
Results Recap is Medtech Insight's exclusive summary of clinical trial results that have been announced or published in the past...
Medtech Insight - October 19, 2018
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Pink Sheet - October 19, 2018
EU Launches Joint Assessment Of Pediatric & Orphan Drugs Legislation
A new European Commission consultation marks the launch of an evaluation exercise to assess the joint impact of the EU...
The Pink Sheet - October 19, 2018
GEn1E gets option to p38 kinase inhibitor IP from UMB
The University of Maryland, Baltimore granted GEn1E Lifesciences Inc. an exclusive option to license intellectual property surrounding selective p38 kinase inhibitors.
Strategic Transactions - October 19, 2018
QUOTED. Oct. 19, 2018. David Skibinski.
SnapMD CEO David Skibinski is very bullish about the central role telehealth will play in cardiology and health care more...
Medtech Insight - October 19, 2018

CDMO Space In Focus As Piramal Mulls Sale
As the Indian business conglomerate Piramal considers the sale of its contract development and manufacturing organization (CDMO), some experts say...
Scrip - October 18, 2018
AbbVie Buys In On Morphic’s Oral Integrin Inhibitors, To Tune Of $100m
After years of industry unsuccessfully trying to find an oral version of the successful I.V. integrin inhibitors, Morphic has a...
Scrip - October 18, 2018
Merck & Co.’s Keytruda/Inlyta Combo Invades Kidney Cancer Territory
Merck & Co.’s IO powerhouse Keytruda has trumped Bavencio’s recent Inlyta combo PFS win in kidney cancer, with a OS...
Scrip - October 18, 2018
Eight Things To Know From Novartis' Third Quarter Call
The company's $2.1bn acquisition of Endocyte and expansion into radiopharmaceuticals dominated some of the call, but with the launches of...
Scrip - October 18, 2018
Medivir Clears The Decks For Clinical Focus, Cuts All Preclinical Projects And 60 Jobs
Medivir outlines plans to cut costs, reduce headcount and streamline priorities as the biotech focuses solely on four assets in...
Scrip - October 18, 2018
Medivir Clears The Decks For Clinical Focus, Cuts All Preclinical Projects
Medivir outlines plans to cut costs, reduce headcount and streamline priorities as the biotech focuses solely on four assets in...
Scrip - October 18, 2018
UCB Pushes On With Potential Myasthenia Gravis Therapy, But Competition Looms
The anti-FcRn MAb, rozanolixizumab, has been found to be effective in myasthenia gravis and has potential in ITP, but other...
Scrip - October 18, 2018
Novartis Tunes Into Radiopharmaceuticals With Endocyte Buy
Endocyte paid just $12m upfront a year ago for a potential first-in-class investigational radioligand therapy for prostate cancer. Novartis is buying...
Scrip - October 18, 2018

Survey Shows Drug Makers Don't Expect To Begin Serializing All Packages By November Deadline
Concerns that the US pharmaceutical industry will not have the necessary serialization systems in place to fully comply with DSCSA...
The Pink Sheet - October 19, 2018
Pharma Q3 Results Preview: Biogen, Gilead, Celgene
Ozanimod re-filing is a big near-term catalyst for Celgene. Biogen investors will be looking for more information about the development...
The Pink Sheet - October 19, 2018
Deal Watch, Licensing & Alliances: Amgen Places $66m Bet On Genetic Sequencing
Already partnered with Oxford Nanopore through its acquisition of deCODE Genetics, Amgen invests in the UK biotech to enhance its...
The Pink Sheet - October 19, 2018
Deal Watch, M&A: Warp Drive And Its Partnerships Acquired By Revolution
Once expected to be absorbed by Sanofi, US biotech Warp Drive Bio now will become part of California’s Revolution Medicines...
The Pink Sheet - October 19, 2018
With TheraFlu PowerPods, GSK Brews Market For OTCs From Coffee Makers
GSK takes Theraflu brand from medicine cabinet to kitchen with launch of PowerPods of OTC ingredients delivered through single-serve coffee...
The Pink Sheet - October 19, 2018
Controversial Dengue Drug Among Six Products To Get EMA Thumbs Up
Dengvaxia, the dengue vaccine from Sanofi that was suspended in the Philippines last year, is among six new products to...
The Pink Sheet - October 19, 2018
Every Little Helps: Shire Product Advances Fortify Takeda's Bid
A positive opinion in the EU for Shire's Takhzyro and a favorable US advisory committee vote for prucalopride are incremental...
The Pink Sheet - October 19, 2018
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Pink Sheet - October 19, 2018
EU Launches Joint Assessment Of Pediatric & Orphan Drugs Legislation
A new European Commission consultation marks the launch of an evaluation exercise to assess the joint impact of the EU...
The Pink Sheet - October 19, 2018

VistaGen Stocks Neuropsychiatry Pipeline And Takes Aim At Depression Market
Shawn Singh, CEO of VistaGen, a growing Silicon Valley-based biotech focused on psychiatry and neurological drug development, outlines the company’s strategy...
IN VIVO - October 17, 2018
Deals In Depth: August 2018
In a partnership worth up to $5 billion, Affimed and Genentech will discovery innate immune cell immunotherapies for solid and...
IN VIVO - October 17, 2018

Only Health-Care Case At US Supreme Court This Fall Looks At Preemption
The Supreme Court will hear arguments this fall in a lawsuit concerning whether FDA decisions can protect drug manufacturers from...
Medtech Insight - October 19, 2018
Medtronic Vet Christopher Barry Takes Helm At Nuvasive
About three years after becoming CEO of NuVasive, Gregory Lucier is ceding the role to Barry, who has led Medtronic's...
Medtech Insight - October 19, 2018
Hong Kong Medtech Regulators Face Need For System Update
Speed and efficiency are apparently on the minds of Hong Kong's regulators, who have proposed to shorten approval times for...
Medtech Insight - October 19, 2018
Q&A: Ireland's Success In Attracting Medtech Companies
Medtech Insight talked to Rachel Shelly, the Head of Medical Technologies for IDA Ireland, about the Irish government's continuing efforts...
Medtech Insight - October 19, 2018
Voters Likely To Pick And Choose Among Device Industry Favorites In Close Races
Among the very tight Republican and Democrat contests anticipated in this November’s US midterm elections are more than a few...
Medtech Insight - October 19, 2018
DATA: Results Recap: Neovasc's Tiara TMVR Succeeds In 12 Patients
Results Recap is Medtech Insight's exclusive summary of clinical trial results that have been announced or published in the past...
Medtech Insight - October 19, 2018
QUOTED. Oct. 19, 2018. David Skibinski.
SnapMD CEO David Skibinski is very bullish about the central role telehealth will play in cardiology and health care more...
Medtech Insight - October 19, 2018

Sparq's Vitamin Vapor Inhalation Product Could Spark Regulatory Interest
Vitamin Air is so novel, it could get FDA's attention for misbranding as a supplement and being an unapproved new...
The Rose Sheet - October 18, 2018
Essential Oil Sleep Claims In Hot Water With UK Advertising Regulator
UK Advertising Standards Authority advised Puressentiel not to make ad claims reserved for licensed medicinal products. Puressentiel argued its products...
The Rose Sheet - October 18, 2018

MeiraGTx acquires AAV gene therapy company Vector Neurosciences for up to $24mm
MeiraGTx Holdings PLC acquired privately held fellow gene therapy biotech Vector Neurosciences Inc. in an all-stock transaction, issuing a total of 225k Class A ordinary shares (valued at $3mm) to Vector’s stockholders.
Strategic Transactions - October 19, 2018
Celltrion, Emory team up in atherosclerosis
Celltrion Inc. is allying with Emory University in the discovery and development of therapies for atherosclerosis.
Strategic Transactions - October 19, 2018
KaNDy Therapeutics raises £25mm in Series C round
UK-based KaNDy Therapeutics (female sex-hormone related conditions) completed a £25mm ($32.2mm) Series C round from new backer Longitude Capital, along with returning investors Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners, and OrbiMed.
Strategic Transactions - October 19, 2018
Morphic closes $80mm Series B
Morphic Therapeutic Inc. (working on oral integrin therapies for autoimmune diseases, fibrotic diseases, and cancer) raised $80mm in its Series B financing led by Omega Funds and Novo Holdings, which each add a board member. New backers Invus and EcoR1 Capital were joined by Series A investors SR One, Pfizer Venture Investments, AbbVie Ventures, Polaris Partners, TA Springer (a board member), Schrodinger, and ShangPharma Investment Group. Morphic will use the proceeds to bring its two lead candidates through clinical proof-of-concept and to move other programs into human studies.
Strategic Transactions - October 19, 2018
AbbVie, Morphic ally in fibrosis
AbbVie Inc. and Morphic Therapeutic Inc. are teaming up to develop the latter’s oral integrin candidates for fibrosis-related indications, potentially including non-alcoholic steatohepatitis (NASH).
Strategic Transactions - October 19, 2018
Oxford Nanopore gets £50mm investment from Amgen
Closely held Oxford Nanopore Technologies Ltd. (genetic sequencing) received a £50mm ($66mm) equity investment from Amgen Inc. in a late-stage financing. Amgen’s deCODE genetics subsidiary has been using Nanopore’s technologies in its own genome research to discover and validate new targets.
Strategic Transactions - October 19, 2018
OliX Pharmaceuticals raises $38mm in IPO on KOSDAQ
South Korean RNAi therapeutics developer OliX Pharmaceuticals Inc. grossed KRW43bn ($38mm) in its initial public offering on the Korea Securities Dealer Automated Quotation (KOSDAQ) market through the sale of 1.2mm shares at $31.67.
Strategic Transactions - October 19, 2018
Aclaris nets $87mm through FOPO
Topical dermatology drug developer Aclaris Therapeutics Inc. netted $87.4mm in a public offering of 8.6mm shares at $10.75. Earlier this month, the company acquired Allergan's Rhofade (oxymetazoline) for $70mm and entered a concurrent loan facility with Oxford Finance. Aclaris will use the proceeds for a portion of the $65mm up-front payment to Allergan, to support commercialization activities for both Rhofade and Eskata (a hydrogen peroxide topical solution for seborrheic keratosis approved in December 2017 and launched earlier this year), and to fund R&D for other pipeline candidates.
Strategic Transactions - October 19, 2018
Novartis buys radiopharmaceuticals company Endocyte for $2.1bn
Novartis AG agreed to acquire public radiopharmaceuticals firm Endocyte Inc. (targeted cancer therapies and companion imaging agents) for $24 in cash per share (a 55% premium), for an equity value of $2.1bn (an enterprise value of $1.9bn, taking into account the company's cash on its balance sheet).
Strategic Transactions - October 19, 2018
PhaseBio nets $42.8mm via IPO
PhaseBio Pharmaceuticals Inc. netted $42.8mm in its initial public offering of 9.2mm common shares at $5 each on the Nasdaq. The company had planned to sell 5mm shares between $12 and $14 each.
Strategic Transactions - October 19, 2018
GEn1E gets option to p38 kinase inhibitor IP from UMB
The University of Maryland, Baltimore granted GEn1E Lifesciences Inc. an exclusive option to license intellectual property surrounding selective p38 kinase inhibitors.
Strategic Transactions - October 19, 2018
Back to the top Back to the top